Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $219000.0.

  • Ligand Pharmaceuticals' Gains from Investment Securities rose 7520.0% to $219000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 24945.91%. This contributed to the annual value of $5.1 million for FY2024, which is 1295.36% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Gains from Investment Securities is $219000.0, which was up 7520.0% from $145000.0 recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Gains from Investment Securities peaked at $11.0 million during Q3 2023, and registered a low of -$10.7 million during Q4 2023.
  • For the 5-year period, Ligand Pharmaceuticals' Gains from Investment Securities averaged around $2.3 million, with its median value being $2.1 million (2022).
  • The largest annual percentage gain for Ligand Pharmaceuticals' Gains from Investment Securities in the last 5 years was 1140833.33% (2023), contrasted with its biggest fall of 58187.56% (2023).
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Gains from Investment Securities stood at $3.3 million in 2021, then plummeted by 32.52% to $2.2 million in 2022, then plummeted by 581.88% to -$10.7 million in 2023, then skyrocketed by 118.1% to $1.9 million in 2024, then plummeted by 88.68% to $219000.0 in 2025.
  • Its Gains from Investment Securities stands at $219000.0 for Q3 2025, versus $145000.0 for Q2 2025 and $8.9 million for Q1 2025.